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Abstract
Background: miRNAs are small, non-coding RNA molecules that mainly act as negative regulators of target gene
messages. Due to their regulatory functions, they have lately been implicated in several diseases, including
malignancies. Roughly half of known miRNA genes are located within previously annotated protein-coding regions
("intragenic miRNAs”). Although a role of intragenic miRNAs as negative feedback regulators has been speculated,
to the best of our knowledge there have been no conclusive large-scale studies investigating the relationship
between intragenic miRNAs and host genes and their pathways.
Results: miRNA-containing host genes were three times longer, contained more introns and had longer 5’ introns
compared to a randomly sampled gene cohort. These results are consistent with the observation that more than
60% of intronic miRNAs are found within the first five 5’ introns. Host gene 3’-untranslated regions (3’-UTRs) were
40% longer and contained significantly more adenylate/uridylate-rich elements (AREs) compared to a randomly
sampled gene cohort. Coincidentally, recent literature suggests that several components of the miRNA biogenesis
pathway are required for the rapid decay of mRNAs containing AREs. A high-confidence set of predicted mRNA
targets of intragenic miRNAs also shared many of these features with the host genes. Approximately 20% of
intragenic miRNAs were predicted to target their host mRNA transcript. Further, KEGG pathway analysis
demonstrated that 22 of the 74 pathways in which host genes were associated showed significant
overrepresentation of proteins encoded by the mRNA targets of associated intragenic miRNAs.
Conclusions: Our findings suggest that both host genes and intragenic miRNA targets may potentially be subject
to multiple layers of regulation. Tight regulatory control of these genes is likely critical for cellular homeostasis and
absence of disease. To this end, we examined the potential for negative feedback loops between intragenic
miRNAs, host genes, and miRNA target genes. We describe, how higher-order miRNA feedback on hosts’
interactomes may at least in part explain correlation patterns observed between expression of host genes and
intragenic miRNA targets in healthy and tumor tissue.
Background
m i c r o R N A s( m i R N A s )a r es m a l l( ~ 2 2 - n t )f u n c t i o n a l
RNA species that provide a newly appreciated layer of
gene regulation with an important role in development,
cellular homeostasis and pathophysiology. miRNAs are
encoded in the genome and transcribed primarily in a
Pol II-dependent manner [1], although Pol III-depen-
dent transcription has also been reported [2,3]. Roughly
half of the known human microRNAs are found in
intergenic regions of the genome, suggesting production
of unique primary transcripts (pri-miRNAs) containing
one or more miRNA hairpins under the control of inde-
pendent promoter elements. The overwhelming majority
of the other ~50% map to previously annotated intronic
regions of protein coding genes, while a small number
are even found within exons. The relationship between
intragenic miRNAs and their host genes presents many
unique questions regarding genomic organization, tran-
scriptional regulation, processing and function.
The genomic organization of intragenic miRNAs exhi-
bits a strong directional bias, such that these species are
predominantly oriented on the same strand of the DNA
as that of the host gene. The directional bias may pre-
vent steric interference between RNA polymerases
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however, the existence of individual antisense miRNA
genes and miRNA gene clusters argues that the primary
evolutionary pressure for the positional bias is co-
regulation of the intronic miRNA and the host gene.
Indeed, microarray analyses supports the hypothesis that
intronic miRNAs are usually expressed in coordination
with the host gene mRNA in human tissues [4,5],
strongly suggesting that co-transcription from the host
gene promoter is the most common transcriptional
mechanism under normal conditions. This assumption
has lately successfully been employed to identify new
miRNA targets [6]. However, recent findings demon-
strate that transcription of a subset of intronic miRNAs
in H. sapiens can be initiated from internal promoters
within operons independently from the host gene [3],
suggesting that utilization of internal promoters must
also be considered a viable alternative strategy for intro-
nic miRNA gene transcription.
Large portions of miRNA processing are understood
(for review see [7]). In brief, a ~70 nucleotide stem-loop
precursor pre-miRNA is excised from a relatively long
primary miRNA transcript, followed by export from the
nucleus via Exportin-5 in a Ran-GTP-dependent man-
ner. In the cytoplasm, pre-miRNAs are further pro-
cessed into a ~22-nt miRNA/miRNA* duplex. In the
case of intronic miRNAs, early steps in the miRNA bio-
genesis pathway are complicated by the requirement for
proper pre-mRNA splicing and mature mRNA assembly
of the host message. Recent bioinformatics and experi-
mental work demonstrates that intronic miRNAs can be
processed from intronic regions co-transcriptionally [8]
prior to the splicing reaction [9]. Interestingly, recent
work suggests that several intragenic miRNAs undergo
post-transcriptional regulation [10], and defects in this
process have been associated with tumor development
[10-14]. The nature of the differences in miRNA proces-
sing and associated defects between intergenic and
intragenic miRNA species is not currently elucidated.
miRNA target recognition in mammals is mainly
mediated via imperfect Watson-Crick base-pairing to
cognate sites primarily located in the 3’-UTR of mRNA
targets. Predicted and validated miRNA targets include a
functionally diverse suite of genes that include many
transcription factors and cell signaling proteins, suggest-
ing a role for miRNAs in regulatory feedback loops
[15-17]. Intragenic miRNAs present unique regulatory
possibilities based on functional relationships with their
host genes. It has been speculated that intronic miRNAs
may directly target their host message or regulate tran-
scription factors, in what is commonly designated “first-
order” or “second-order” negative feedback, respectively
[18]. Recently published work [19] demonstrates that
miR-338, encoded in an intron of the apoptosis-
associated tyrosine kinase (AATK) gene, targets several
genes that are functionally antagonistic to the AATK
protein. Therefore, miR-338 serves the functional inter-
est of the host in this case via a higher-order positive
feedback system that downregulates expression of
AATK repressors and enforces neuronal differentiation
downstream of the kinase.
In the current manuscript, large-scale bioinformatics
analyses of human intronic miRNAs related to genomic
organization and characterization of miRNA host and
target genes are presented. We identify characteristics of
host genes and predicted targets, and present evidence
that intragenic miRNAs may act as negative feedback
regulatory elements of their hosts’ interactome (i.e., they
can regulate host gene neighbours in addition to host
genes).
Results
We integrated genomic and transcriptomic information
to analyze properties of intragenic miRNAs themselves,
their host genes, as well as their targets. We used all
k n o w nm i R N A s( b a s e do nm i R B a s e ) ,a l lk n o w nh u m a n
transcripts (based on RefSeq), six different and highly
established miRNA target prediction algorithms, as well
as the gene and pathway annotation ontologies GO and
KEGG.
Classification of miRNAs
Based on mapping miRNA genomic coordinates to
genomic position of all known genes and their exons
and introns (based on RefSeq sequences [20]), we could
classify miRNAs into three classes: intergenic, exonic,
and intronic (Table 1). For H. sapiens, 296 miRNAs
were located within intronic regions, and 37 within exo-
nic regions of known genes. We also classified miRNAs
from other species (Table 1). Interestingly, organisms
that have a well-annotated set of protein-coding genes
present distributions that resemble that of the miRNA
distribution in humans, showing 33-48% of intronic
miRNAs and 0.6-6% of exonic miRNAs (Table 1, organ-
isms M. musculus, D. melanogaster and C. elegans). On
the other hand, organisms containing a smaller number
of annotated genes presented a higher number of inter-
genic miRNAs (Table 1, organisms C. familiaris, G. gal-
lus and D. rerio), some of which however may become
intragenic as more genes will be identified in these
organisms. Additional file 1 contains details of miRNAs
classification, their genomic position and host genes.
Positional Bias of Intragenic miRNAs
The orientation of the gene for an intronic miRNA
depends significantly on the transcription direction of
its host gene (p-value = 1.3 × 10-36 in c
2 test) as shown
in Table 1. We found that 65.5% of host genes had
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that the observed distribution differs significantly from
the expected distribution within the first five introns
(p = 0.030 in c
2 test, additional file 2).
Characterization of Host Genes
Assuming, as is widely accepted, that intragenic miRNAs
share a common regulatory control with their host
genes, we can infer functional aspects of this class of
miRNAs by characterizing features of those host genes.
To confirm that the position of miRNAs has a particular
bias, and is not the result of chance, we randomly
sampled genes that matched the set of miRNA host
genes (in terms of chromosome and strand distribution)
and compared the positions of host, target, and ran-
domly sampled genes. The findings are summarized in
Table 2. Host genes are almost three times longer than
the randomly sampled cohort and have more introns.
When comparing the intron size in different positions
( F i g u r e1 a ) ,w ef o u n dt h a tt h ef i r s tf i v e5 ’ introns are
significantly longer, consistent with our previous finding
that most host genes’ intronic miRNAs are found in the
5’ introns (Figure 1b).
Gene expression can be pre- and post-transcriptionally
controlled through regulatory motifs in their 3’-UTRs.
Even though regulatory mechanisms are not well under-
stood, two important concepts include regulation
through miRNAs, and the role of adenylate/uridylate-
rich elements (AREs) in mediating mRNA decay, which
plays a significant role in cancer development [21-23].
We first compared the length of the 3’-UTRs of host
genes to the length of 3’-UTRs of the random sample.
Host genes have 40% longer 3’-UTRs (p-value <0 . 0 1 ) .
In a second step, we counted occurrences of the penta-
mer AUUUA in these regions, normalized by the length
of the 3’-UTRs. We found significantly more ARE units
Table 1 Classification of miRNAs in the Genome of Different Species
Organism Intragenic miRNAs Intergenic miRNAs Intragenic miRNAs
Intronic Exonic miRNAs on Host Gene
Strand
miRNAs on Opposite
Host Strand
Homo sapiens 296 (42.6%) 37 (5.3%) 362 (52.1%) 282 (84.7%) 51 (15.3%)
Mus musculus 171 (35.4%) 30 (6.2%) 282 (58.4%) 163 (78.2%) 38 (21.8%)
Canis familiaris 3 (1.5%) 0 (0%) 201 (98.5%) 2 (66.7%) 1 (33.3%)
Gallus gallus 50 (10.7%) 1 (0.2%) 418 (89.1%) 46 (90.2%) 5 (9.8%)
Danio rerio 48 (15.0%) 1 (0.3%) 271 (84.7%) 39 (79.6%) 10 (20.4%)
Drosophila melanogaster 65 (42.8%) 2 (1.3%) 85 (55.9%) 53 (79.1%) 14 (20.9%)
Caenorhabditis elegans 51 (33.1%) 1 (0.6%) 102 (66.2%) 33 (63.6%) 19 (36.5%)
Intragenic miRNAs are found in many different species. However, the distribution of intra- and intergenic miRNAs differs. These numbers are obtainedb y
crossing miRNA genomic coordinates with known transcript coordinates (based on RefSeq sequences).
Table 2 Properties of Host and Target Genes
Property Gene Set Median[Range] Host/Target Median[Range] Control Ratio p-Value
Total length (basepairs) Host Genes 84871.0 [2792-2220381] 29324.5 [599-2304633] 2.89 < 2.2e-16
Target genes 83747.5 [2366-2220381] 30232.5 [218-2220381] 2.77 < 2.2e-16
Introns Host Genes 13[1-88] 8[1-105] 1.62 4.3e-13
Target genes 10.5[0-78] 8[0-311] 1.31 9.77e-07
Length 5’UTR (basepairs) Host Genes 279.5[0-385608] 298.5[0-1098107] 0.94 0.25
Target genes 439.5[0-460277] 282.5[0-1098107] 1.56 2.32e-08
Length 3’UTR (basepairs) Host Genes 1218.5[0-535884] 872[0-321862] 1.4 4.71e-05
Target genes 1764[171-11799] 872[0-72058] 2.2 < 2.2e-16
ARE (absolute) Host Genes 2.0[0-1794] 1.0[0-592] 2.0 3.89e-04
Target genes 5.0[0-47] 2.0[0-187] 2.5 < 2.2e-16
ARE (per kb) Host Genes 1.9[0-2.74] 1.49[0-0.045] 1.26 0.012
Target genes 2.69[0-14.22] 1.63[0-76.92] 1.65 < 2.2e-16
5’ UTR GC content Host Genes 0.6[0.31-0.95] 0.59[0-1] 1.06 0.015
Target genes 0.59[0.26-1] 0.58[0-1] 1.01 0.71
Host and target genes display similar properties, compared to a set of control genes, including increased length, higher number of total introns, longer 3’UTRs
and higher frequency of “AU-rich elements” (AREs).
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Page 3 of 13Figure 1 Intragenic miRNA Properties. (a) The sizes of host gene introns closest to the TSS are significantly larger than those of respective
controls. (b) Intronic miRNAs appear to be unevenly distributed across the intronic regions of their host genes. More then half of intronic
miRNAs are located within the first five 5’ introns of their hosts. (c) The observed target coverage (diamond) is at the upper end of the random
distribution of target coverages for different signaling pathways, indicating that intragenic miRNAs have more targets within the pathway than
would be expected by chance. (d) Intragenic miRNAs may control their host in the setting of a negative feedback circuitry not only through
direct regulation of the host’s transcription, but also on the order of the interactome, by controlling other genes in the host’s pathway.
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0.01). Since recently miRNA target genes have been
shown to be larger than non-target genes [24], we ana-
lyzed total lengths and lengths of 3’-UTRs [25] for host
genes predicted to be targeted by their intragenic
miRNA and the remaining host genes separately. No
significant difference in lengths between the two groups
of host genes was observed (p-value = 0.3939), but
genes in both groups were longer than genes in the con-
trol group (p-value = 1.552e-07 and p-value <2 . 2 e -
16).3’-UTRs were longer in host genes predicted to be
targets of their intronic miRNA than in host genes not
predicted to be targets (p-value = 0.001) and control
genes (p-value = 5.012e-07). In contrast, the 5’-UTRs of
host genes were not significantly longer than the ones in
the control group (p-value > 0.05).
The GO Biological Process (GOBP) and KEGG are
ontologies that associate genes with, cellular processes
and biochemical pathways, respectively, including dis-
ease pathways. When surveying GOBP for overrepresen-
tation of miRNA host genes in certain categories, we
found significant enrichment in gene regulatory, meta-
bolic, neurogenic, and cytoskeletal processes, which
reflects the broad range of diseases with which miRNAs
have been associated [12,26-34]. Additionally, we found
that host genes were overrepresented in several signaling
pathways, such as the MAPK, ErbB, VEGF, and the cal-
cium signaling pathway.
Genomic Properties of Target Genes
We looked at genomic properties of a high-confidence
set of targets for hosts of intronic miRNAs (prediction
agreement ≥ 6) that would give us a set of similar size
as the host genes. We then randomly sampled RefSeq
transcripts to match chromosome and strand distribu-
tion as a control set and performed the analysis analo-
gously to the analysis of genomic properties of the host
genes themselves. Table 2 summarizes the results,
revealing that the predicted targets have properties that
are highly similar to those of host genes.
Relationship Between Intragenic miRNAs and Host Genes
We found that approximatelly 20% of intragenic miRNAs
(56 of them, hosted in 49 distinct genes) are predicted to
target their own host by at least two methods. This num-
ber is significantly higher than would be expected by
chance alone (p-value < 0.001, obtained by random sam-
pling). Furthermore, we assessed the robustness of our
approach by following the above procedure while apply-
ing a voting method as the gold standard. We assigned
each of the target prediction methods to one of two
g r o u p so fe q u a ls i z e( n=3 )a n dr e q u i r e da tl e a s to n e
vote from each group to consider that a prediction of a
miRNA-host interaction. TarBase did not contain a single
instance of miRNA-host interaction, so it was excluded
from the analysis. Although the numbers of miRNAs pre-
dicted to target their own host varied (12 - 55), depend-
ing on which group they had been assigned to, in each
case the observed number was significantly higher than
would be expected by chance (p-value < 0.05, see also
additional file 3). Given that host genes that were pre-
dicted to be targets of their intragenic miRNA have
longer 3’-UTR regions, statistical significance of the num-
ber of hosts being targeted by their intronic miRNAs was
assessed by repeated creation of sets of non-host control
genes with similar 3’-UTR distribution (see Materials and
Methods). In line with our previous observations, the
number of hosts predicted to be targeted by their intra-
genic miRNAs (49) was significantly higher than
expected by chance (p-value = 0.032).
In order to test the hypothesis that intronic miRNAs
might act as regulators even in the global functional
context of a negative feedback loop circuitry, the
KEGG pathway analysis was extended to identify tar-
gets within the respective biomolecular pathway. We
defined the target coverage as the number of genes
within a pathway that were predicted targets (predic-
tion agreement ≥ 2) of miRNAs residing in host genes
within that pathway, over the total number of genes in
the pathway. To check whether the observed target
coverage could be expected by chance, the original
genes contained in the pathway were replaced by a set
of randomly sampled genes and the expected target
coverage of intronic miRNAs with host genes in a par-
ticular pathway was calculated. The distributions of
expected target coverage for three signaling pathways
are visualized in Figure 1c. At a false discovery rate
(FDR) of 10%, 22 out of 74 pathways with which host
genes were associated showed a significant overrepre-
sentation of targets in the hosts’ pathways (Table 3,
Additional File 5). Interestingly, many signalling and
malignancy-related pathways ranked high.
Implications for Cancer Pathogenesis
Integration of major KEGG pathway information with
expression data from two publicly available datasets
[35,36] helped us investigate the idea of loss of negative
feedback circuitry.
KEGG ID “05215 - Prostate Cancer” contains a single
known miRNA host (AKT2), and it is not predicted to be
targeted by its intronic miRNA (hsa-miR-641). The corre-
lation between the expressions of host and predicted tar-
gets involved in the pathway were calculated. Figure 2
shows a simplified representation based on the KEGG
pathway information. Host and corresponding targets are
color-coded, where the green oval indicates the host,
AKT2, and yellow, orange, and red indicate whether two,
three or four methods agreed on the target prediction.
Hinske et al. BMC Genomics 2010, 11:533
http://www.biomedcentral.com/1471-2164/11/533
Page 5 of 13In line with the hypothesis of an interactome feedback
circuitry, predicted targets of hsa-miR-641 appear to be
in close proximity and in functional synergy with its host.
A similar target pattern is displayed by both miRNAs,
hsa-miR-641 and hsa-mir-634, in the non-small-cell lung
cancer pathway (additional file 4).
The correlation between host and target expression
levels is shown in a two-bar plot. The first bar, labeled
“N”, represents the correlation between host and target
in normal tissue. The second bar, labeled “T”, represents
the correlation between host and target in cancerous tis-
sue. In the prostate cancer dataset, seven of the fifteen
targets are more negatively correlated in healthy tissue
than in cancer. In four cases (AKT3, AR,M A P K 1 ,a n d
CTNNB1), we could observe a significant negative corre-
lation in normal tissue, which was either non-significant
or was significantly positive in cancer. A similar pattern
could be observed in the non small cell lung cancer
pathway.
Discussion and Conclusions
Since the first discovery of miRNAs, our understanding
of biogenesis and regulation has exponentially grown. In
the recent past, it has been estimated that miRNAs that
reside in intronic or exonic regions of other genes may
be the dominating class [9]. However, functional aspects
of intragenic miRNAs are still largely unknown.
It is generally believed that both host and miRNA
share regulatory control [4-6], although a recent study
found that transcription of roughly 30% of intragenic
miRNAs may be initiated independently [3]. After map-
ping miRNAs to known genes, we found that most
intronic miRNAs are oriented in the same direction as
their host gene, significantly more than would be
expected by chance. Several hypotheses related to this
preferential orientation have been suggested. First, most
of intragenic miRNAs may not present their own pro-
moter and be dependent to the transcription of their
host gene. Second, miRNAs may present their own pro-
moter, and directional bias may prevent physical inter-
ference between RNA polymerases transcribing the host
gene and RNA polymerases transcribing the miRNA
gene [4].
Baskerville and Bartel identified significant correlation
between the expression levels of intronic miRNAs and
their host genes, suggesting co-regulation [4]. We
Table 3 Pathways with Overrepresentation of Genes Targeted by an Intronic miRNA
Pathway Host Genes in Pathway Target Coverage p-Value q-Value
MAPK Signaling ATF2; DDIT3; AKT2; FGF13; ARRB1; PPP3CA; PRKCA; CACNG8; RPS6KA2;
MAP2K4; RPS6KA4
61.4% < 0.001 < 0.001
Axon Guidance PPP3CA; PTK2; SEMA4G; SEMA3F; SLIT3; ABLIM2; SLIT2 70.3% < 0.001 < 0.001
Ubiquitin Mediated Proteolysis HUWE1; WWP2; BIRC6; ITCH 53.8% < 0.001 < 0.001
Focal Adhesion COL3A1; AKT2; PRKCA; PTK2; TLN2 49.5% < 0.001 < 0.001
Glioma AKT2; PRKCA 52.3% < 0.001 < 0.001
Melanoma AKT2; FGF13 50.7% < 0.001 < 0.001
Regulation of Actin Cytoskeleton CHRM2; FGF13; SSH1; PTK2 41.0% < 0.001 < 0.001
Chronic Myloid Leukemia AKT2 38.2% < 0.001 < 0.001
Colorectal Cancer AKT2 35.7% < 0.001 < 0.001
Prostate Cancer AKT2 34.8% 0.001 0.007
Melanogenesis PRKCA 21.6% 0.001 0.007
Pancreatic Cancer AKT2 35.6% 0.002 0.01
ErbB Signaling ERBB4; AKT2; PRKCA; PTK2; MAP2K4 51.7% 0.003 0.02
Glycan Structures Biosynthesis MGAT4B; FUT8; CSGLCA-T; GALNT10; HS3ST3A1 50.8% 0.003 0.02
Gap Junction HTR2C; PRKCA; PRKG1 47.9% 0.005 0.02
Non-Small Cell Lung Cancer AKT2; PRKCA 42.6% 0.007 0.03
Small Cell Lung Cancer AKT2; PTK2 35.6% 0.013 0.05
Long-Term Depression PRKCA; PRKG1 33.3% 0.014 0.05
Insulin Signaling AKT2; SREBF1 36.0% 0.014 0.05
Long-Term Potentiation PPP3CA; PRKCA; RPS6KA2 27.1% 0.005 0.06
T-Cell Receptor Signaling AKT2; PPP3CA 32.3% 0.016 0.09
Wnt Signaling PPP3CA; PRKCA 21.6% 0.020 0.09
22 out of 74 pathways containing host genes show a significant overrepresentation of targets within the pathway at a FDR of 10%. Host genes that were
predicted targets of their own miRNA were removed from the count. Interestingly, the list of pathways contains many pathways crucial for development and
signal transduction, or associated with neoplastic transformation.
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miRNAs are found in the 5’ regions of their host genes,
where introns are firstly excised. It is well known that
transcriptional activity is higher towards the 5’ region of
a gene [37] and also that regulatory motifs tend to
reside in these regions [38]. From a functional perspec-
tive, these findings may suggest dependency between
host and miRNA transciption. In order to characterize
the relationship between intronic miRNAs and their
hosts, we identified properties of the set of host genes,
as well as a set of high confidence targets. Whereas
Golan et al. [39] showed in a recent work that intronic
miRNA density is lower in large host genes, we provided
evidence that the class of host genes in general is signifi-
cantly longer and contains more and larger introns. This
increases transcriptional efforts for the cell and is con-
sidered a characteristic of tightly regulated genes [40].
Interestingly, these features can also be found in a high-
confidence set of targets (i.e. prediction agreement ≥ 6
methods), which may support the idea of miRNAs as
regulators of their own host genes. Additionally, the 3’-
UTRs of host genes predicted to be targeted by their
own miRNA are significantly longer, exposing the mes-
sage to more regulatory control mechanisms, such as
targeting by miRNAs or ARE mediated mRNA decay.
Interestingly, host genes contain significantly more
AREs. Many of these properties have been shown to be
features of proto-oncogenes and the sum of these find-
ings may suggest tight regulatory control of these genes
[21,23,41]. Surveying GOBP and KEGG pathways, we
found host genes to be associated with metabolic, bio-
synthetic, gene regulative processes, and signaling path-
ways. These categories capture major functional aspects
of miRNAs in general, as is reflected by miRNA involve-
ment in diseases such as cancer [32], muscle disorders
[27], or neurodegenerative diseases [42]. We then
assessed predicted targets, using agreement between six
distinct prediction algorithms and a database of vali-
dated miRNA targets as a measure of confidence. First,
we identified 56 miRNAs predicted to target their own
host. Interestingly, more of these miRNA-host gene
pairs are conserved than of the remaining miRNA-host
gene pairs (Table 4). Recently, Sun et al. validated the
predicted interaction between hsa-miR-126 and its host
Figure 2 Correlation of Predicted miRNA Targets with Hosts.T h ePI3K - PKB/AKT pathway is believed to be a key component in cancer
development. We compared correlation of miRNA predicted targets (prediction agreement ≥ 2) to the respective host in normal (N) and tumor
(T) tissue. Several of the hypothesized targets display features predicted by our model, such as AR, PDGFB, PDGFRB, AKT3 and MAPK1.
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these predictions, we observed for 22 of the 74 pathways
that host genes were associated with a higher number of
targets within the pathway than would be expected by
chance alone. A visual representation of the targets of
AKT2’si n t r o n i cm i R N Ahsa-miR-641, for example,
showed how components of many protein complexes
involved in the signal transduction of growth factor sig-
nalling may be potential targets of hsa-miR-641 (Figure
2). The combination of these findings indicates that
intragenic miRNAs may play a role in interactome feed-
back circuitries, as visualized in Figure 1d, as an addi-
tional security switch for genes requiring narrow
control. A subset of up to 20% of intragenic miRNAs
may directly regulate the host expression (we referred to
this phenomenon as “first-order feedback”). Moreover,
intragenic miRNAs display targeting patterns that
appear not only to influence their hosts’ expression
levels, but also their functional environment. The obser-
vation that structural properties of a set of high-confi-
dence-prediction target genes, such as long 3’-UTRs,
length, and number of AREs, resemble those of host
genes emphasize the concept of regulation of interacting
gene products in highly restricted settings.
Loss of negative feedback control systems is a well-
known mechanism by which cancer develops. Blenkiron
and coworkers [11] recently suggested that miRNA pro-
cessing might be disturbed in cancer. If expression levels
of intragenic miRNAs are reduced, as observed by some
authors [13,45], subsequently important signalling path-
ways may lose inhibition and this may facilitate uncon-
trolled cell growth. In a recent study, Tavazoie et al.
analyzed six miRNAs that were significantly under-
expressed in breast cancer LM2 cells, as compared to
normal breast tissue. Four of these miRNAs were intra-
genic [46]. The authors reported that loss of the intronic
miRNA hsa-miR-335, which resides in intron 2 of its
host gene MEST, led to increased migration and inva-
sion rates and hence increased metastatic capacity.
Additionally, they could show that hsa-miR-126 (intron
7, host EGFL7) significantly reduced proliferation of
breast cancer cells. Likewise, hsa-miR-151 has been
shown to be downregulated in chronic myloid leukemia
through BCR/ABL [47], and silencing its host gene
PTK2 inhibits leukemogenesis [48]. A similar pattern
can for example be found for hsa-miR-504 and FGF13
[49,50].
Changes in miRNA biosynthesis such as those found in
cancer can interfere with the coordination of expression
of miRNA and host. Thus, a negative correlation between
expression levels of host and genes targeted by its intra-
genic miRNA in normal tissue (given that the host is not
targeted by the miRNA it contains) and a less negative or
even positive correlation in cancerous tissue might be
expected. This phenomenon was observed in two distinct
datasets in different malignancies (Figure 2, additional file
4 and additional file 6). A key to pathogenesis of both
entities is the phosphatidylinositol 3-kinase(PIK3)/AKT
signaling pathway, deregulation of which has been
reported in several cancers, including prostate cancer
[51], lung cancer [52], ovarian cancer [53,54], breast can-
cer [53,55], and colon tumors [54]. Whereas Noske et al.
discovered that silencing AKT2 through RNA interfer-
ence leads to reduction in ovarian cancer cell prolifera-
tion [56], Maroulakou and coworkers reported
accelerated development of polyoma middle T and
ErbB2/Neu-driven mammary adenocarcinomas in mice
after AKT2 ablation [57]. Although these findings would
appear to be contradictory at first, they can be explained
by an intragenic miRNA-driven negative regulatory loop
that is disturbed in cancer. Whereas in the first experi-
ment AKT2 was targeted on mRNA level (and therefore
mimicking the role of the corresponding intronic
miRNA), in the second experiment both host mRNA and
miRNA (if it exists in mouse) were downregulated, and
therefore may have disabled a potential negative feedback
regulation by hsa-miR-641.
One must remember, however, that regulatory net-
works are far more complex in reality than what we are
currently able to model. Transcription factors, enhancers,
silencers, and epigenetic modifications play major roles in
cancer development and may influence correlation
among expression levels of hosts and targets. Also, target
prediction methods are error prone, and at this point we
can only speculate about the true nature of events and
therefore plan to conduct further experiments in which
Table 4 Conservation of miRNA-Host Pairs
Organism miRNA-Host Pairs Predicted to Target own
Host
miRNA-Host Pairs Not Predicted to Target own
Host
p-Value
Conserved Total Conserved Total
Homo sapiens - Mus musculus 18 (35.2%) 51 41 (24.5%) 167 0.18
Homo sapiens - Canis familiaris 1 (2.12%) 47 0 142 0.56
Homo sapiens - Gallus gallus 5 (12.5%) 40 1 (0.71%) 139 0.001
The subset of intragenic miRNA host pairs where the miRNA is predicted to target its own host shows a tendency to be more conserved. However, statistical
significance can only be shown for conservation between human and chicken (2-sample test for equality of proportions with continuity correction).
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integrating different target prediction methods, roughly
20% of intragenic miRNAs were predicted to target their
own host. Though this number is significantly higher
than expected by chance, it still does not cover the
majority of miRNAs. For one, this number may underes-
timate the true number of miRNAs targeting their own
host due to limitations of target prediction methods.
Additionally, it has lately been shown that transcription
of one third of intronic miRNAs can be initiated inde-
pendently of the host’s transcription [3], in which case
direct feedback cannot be claimed. Also, we only investi-
gated feedback on the level of direct miRNA-host interac-
tion and on the order of the interactome based on the
KEGG database. However, knowledge about interaction
of proteins is still limited and cotranscription of host and
miRNA may enable more complex mechanisms. Limita-
tions to current knowledge may also justify, why a signifi-
cant fraction of predicted targets in do not show the
expected behaviour. Indeed, Cyclin E and E2F in Figure 2
show opposite behavior than what we would expect.
Neither of these genes might actually be a target of hsa-
miR-641; there may also exist stronger regulating ele-
ments that control their expression, or the primary mode
of silencing in that specific situation may be through
translational repression. Nevertheless, it is interesting
how key molecules in two different datasets displayed
predicted correlation patterns.
Further experiments and biological validation of com-
putational evidence presented here may have great impli-
cations, especially in cancer therapy. Modern therapies
usually target central molecules, such as AKT and PI3K
with some success. However, these techniques control
only single elements in a cascade of complex signalling
events. In summary, our findings encourage more focused
research on intragenic miRNAs and their targets.
Methods
Classification of miRNAs
miRNA genomic coordinates from miRBase release 11
(April 2008) [58-60] were crossed to genomic coordi-
nates of RNA Reference Sequences (http://www.ncbi.
nlm.nih.gov/RefSeq; Release 31) [20] downloaded from
UCSC Genome Browser http://genome.ucsc.edu. To
each genomic mapped RefSeq sequence, a single gene
was assigned. The subset of miRNAs whose coordinates
mapped to an annotated gene was defined as intragenic.
Intragenic miRNAs were classified as exonic when their
coordinates overlapped with any observed exonic region,
and intronic otherwise.
Host Genes’ Intronic miRNA Distribution
Introns were sequentially enumerated based on gene
orientation. For each intron number, host genes
containing miRNAs in this intron were counted. We cal-
culated the expected number of genes containing an intro-
nic miRNAs in a given intron number by adding all intron
lengths of introns with the respective intron number and
dividing it by the summed length of all host genes’ introns,
thus accounting for intron frequency and length.
Gene Ontology
The Gene Ontology [61] classifications of all 246 host
genes of intragenic miRNA genes that were located on
the same strand as their host gene were surveyed using
Cytoscape 2.6.0 [62] and BiNGO 2.3 [63]. We focused
our attention on those categories that were dispropor-
tionately overrepresented. The setting “Hypergeometric
test” was chosen to calculate the probability of observing
an equal or greater number of genes in a given func-
tional category than in the test set. The False Discovery
Rate (FDR), which is the standard setting in BiNGO 2.3
[63], was controlled.
Pathways identification
The statistical programming software R 2.7.1 was used in
combination with Bioconductor [64,65] packages
AnnBuilder 1.18.0, KEGG.db version 2.2.0, and GOStats
version 1.7.4 to acquire a list of pathways that were asso-
ciated with one or more of the 246 host gene proteins.
Target Predictions
Strategies to perform high-throughput miRNA target
validation are still very limited. Therefore, target predic-
tion algorithms are employed to allow large-scale assess-
ment of miRNA-target interaction. However, usage of
target prediction methods raises two difficulties. First,
target prediction methods are known to suffer from a sig-
nificant number of false positive predictions. We rea-
soned that a possible way to address this problem would
be to estimate statistical significance by generating back-
ground distributions by the very same methods. Hence, if
target predictions were too close to random, the mean of
the generated background distribution should be close to
the observed number, whereas a significant finding
should not be affected by the absolute number of false
positives. Second, different target prediction algorithms
incorporate different types of information about miRNA
target interactions. To overcome individual biases that
m a yb ei n t r o d u c e db yo n es p e c i f i cm e t h o da n du s et h e
wide range of experimental knowledge gained, we inte-
grated predictions from six current algorithms. Precalcu-
lated target predictions for TargetScan release 4.2 [66]
(April 2008), PITA [67] catalog version 6 (August 2008),
MirTarget2 (mirDB) version 2.0 [68,69] (December
2007), miRanda [70] (September 2008), RNA22 [71]
(November 2006) and PicTar 5-way [72] were down-
loaded. We also included TarBase version 5.0c [73] (June
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tions with published evidence; only targets with a “Sup-
port Type” value of either “True” or “Microarray” were
selected. Some miRNA symbols did not exactly match
entries in the database for various reasons, including use
of non-official names or older miRBase releases. When-
ever a miRNA symbol could not be found, matching was
attempted to an extension such as “-1” or “a” (for exam-
ple, hsa-mir-511 in mirTarget2 was matched to hsa-mir-
511-1 and hsa-mir-511-2). If the miRNA symbol ended
with a letter, it was removed to check for other matches
(from the PicTar prediction list hsa-mir-128a matched to
hsa-mir-128-1, hsa-mir-128-2,a n dhsa-mir-128-3 for
example). Predictions for a miRNA symbol were ignored
if no matches could be found. Due to the diversity of
underlying principles, assumptions, and scoring systems,
we defined the prediction agreement, i.e. the number of
methods that agree on a certain miRNA target predic-
tion, as a measure of confidence in the target prediction.
In recent work, Selbach et al. measured changes in pro-
tein and mRNA expression after transfection and overex-
pression of five different miRNAs (hsa-miR-1, hsa-miR-
16, hsa-miR-30a, hsa-miR-255, hsa-let-7b) in HeLa cells
[74]. We evaluated the different target prediction meth-
ods used in this study by measuring the abundance of
predicted products (mRNA or the proteins encoded by
these mRNAs, a continuous value) and assessing discri-
mination by areas under the ROC curve using the pre-
dicted targets as the binary outcome. All five miRNA
datasets were pooled (see additional file 3 for details).
The AUC (Area under Receiver Operator Characteristic
( R O C )C u r v e )m e a s u r e sh o ww e l lp r e d i c t i o n sa n dn o n -
predictions can be discriminated at all possible thresh-
olds, with a value of 0.5 indicating no discrimination and
a value of 1 indicating perfect discrimination. Target pre-
diction methods varied greatly in AUCs, ranging from
0.55 to 0.92 in protein measurements. With increasing
prediction agreement, an almost linear increase in AUC
can be observed, indicating that prediction agreement
may be used as a proxy for the confidence of a predicted
miRNA target interaction (Figure 3).
Gene Expression Datasets
Two publicly available mRNA expression datasets
(GSE6956, GSE7670) were downloaded from the Gene
Expression Omnibus http://www.ncbi.nlm.nih.gov/geo.
We included 87 prostate samples (69 tumor and 18
healthy tissue samples) [35] and 60 lung samples (31
non-small-cell lung cancer and 29 healthy lung tissue
samples) [36]. Preprocessing was carried out using Bio-
Conductor packages [64,65]. Data from protein and
mRNA expression change after miRNA transfection
experiments were downloaded from http://psilac.mdc-
berlin.de[74].
Genomic Host and Target Gene Properties
In order to assess genomic properties of host genes
(n = 246), we constructed a set of control genes (n =
2460) that would match chromosome and strand dis-
tribution of host genes in order to exclude structural
differences due to chromosomal specificities. We
defined miRNA target interactions predicted by at least
6m e t h o d sa s“high confidence targets” (n = 326).
These predictions cover 33 host genes and 43 miRNAs
when at least six methods are required and 239 hosts
and 272 miRNAs when at least 2 methods are
required. Statistical testing was done using Mann-
Whitney-U test. For the analysis of total length and 3’-
UTR length of host genes, hosts were additionally split
into two groups, dependent on whether they were pre-
dicted to be targets of their intragenic miRNA. We
combined the Kruskal-Wallis rank sum test with post-
hoc pairwise Mann-Whitney-U test with Bonferroni
correction (p < 0.016 defined as significance cut-off for
three pairwise comparisons). Assessment of host genes
predicted to be targeted by their intragenic miRNAs
was carried out as follows: Out of the 2460 control
genes, we sampled 1000 sets of genes of size 246 that
would match the host gene 3’-UTR length distribution
(no significant difference in Mann-Whitney-U test).
Intragenic miRNAs were assigned to genes in the sets
and the number of genes predicted to be targeted by
that miRNA was calculated. Similarly, the observed
number of miRNAs predicted to target their own host
was assessed by exchanging host genes for randomly
chosen genes from predicted targets and recalculation
of the number of miRNAs predicted to target their
host. Robustness of this approach was tested by addi-
tionally requiring a vote from each of two groups of
three prediction methods each.
Figure 3 Prediction Agreement as a Measure of Confidence.
When constructing an ROCs on protein measurements, there is an
almost linear relationship of the resulting AUCs and prediction
agreement. This is also true for mRNA measurements, though the
slope is less steep.
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HomoloGene database NCBI release 61 http://www.ncbi.
nlm.nih.gov/homologene and mirBase release 11 (April
2008) [58-60] were used to identify homologous host
genes in Homo sapiens, Canis familiaris, and Gallus gal-
lus. Proportions of conserved miRNA-host gene pairs
for miRNAs predicted and miRNAs not predicted to
target their own host were calculated. Similarly, we used
information on target site conservation from TargetScan
to calculate the proportion of conserved targetsites of
predicted target host interactions in the hosts’ pathway
and of those not in the hosts’ pathway. Statistical signifi-
cance was assessed using the 2-sample test for equality
of proportions with continuity correction.
Target Coverage
The union of predicted targets included more than 90%
of all known human genes. Since target prediction
methods are very different, they are difficult to compare.
In this work, only targets that were predicted by at least
two different methods were considered in the calcula-
tion of target coverage. This reduced the total number
of predictions by almost 70%.
We defined the set Sp as the set of genes linked to a
pathway and St as the set of predicted targets of the miR-
NAs associated with the pathway through their host genes.
The target coverage (C) for a pathway was defined as
C
Sp St
Sp
=
∩ ||
||
.
Statistical significance of target enrichment within a
pathway was tested by randomly sampling |Sp| genes
from a universe of all known genes, replacing the genes
within the pathway with the set of genes in the random
sample (Si), and subsequently calculating a new “ran-
dom” target coverage Ci’. This procedure was repeated
1000 times, allowing estimation of the probability as the
number of times a target coverage Ci’ greater or equal
to C was observed. We defined the indicator function I
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Analogously, the enrichment statistics for miRNAs
targeting their own hosts were calculated, where Sp was
d e f i n e da st h es e to fh o s tg e n e s ,St as the set of targets
of the intragenic miRNAs of these host genes, and Si as
the set of |Sp| randomly sampled genes (out of the non-
redundant set of predicted targets for these miRNAs).
The R-package ‘q-value’ was used to account for multi-
ple hypothesis testing by controlling the False Discovery
Rate (FDR) to be < 10%.
Additional material
Additional file 1: Additional Information on Intragenic miRNAs.T h e
table in additional file 1 contains information on intragenic miRNAs, such
as genomic position, name and RefSeq ID of the host gene, and
orientation.
Additional file 2: Distribution of intragenic miRNAs. Additional file 2
contains an additional barplot showing the distribution of intronic
miRNAs across their hosts’ introns, as well as a theoretically expected
distribution taking intron frequency and size into consideration. The first
figure on page 1 shows a barplot of expected and observed distribution
of intragenic miRNAs across their hosts’ interactome. The second figure is
a repetition of Figure 1b, for better comparison. The second page
contains the underlying data in table format.
Additional file 3: Evaluation of Target Prediction Methods. Based on
protein and mRNA expression measurements in miRNA transfection
experiments, we evaluated the target prediction methods used in this
study, as well as prediction agreement as a method of its own. We
estimated sensitivity, specificity, and AUC for target prediction methods
used and prediction agreement based on the Selbach data [74] for
changes in mRNA and protein expression after miRNA overexpression.
Additional file 4: Non Small Cell Lung Cancer. The figure is analogous
to Figure 2, for a non small cell lung cancer mRNA expression microarray
dataset.
Additional file 5: Full Pathway Information. The table provides all 74
KEGG pathways associated with one or more host genes. For each KEGG
pathway KEGG ID, pathway name, p-value and odds ratio for the
observed number of host genes, total number of expected genes, total
number of observed genes, total number of genes in that pathway,
pathway url, host gene names and Entrez-IDs, target coverage and p-
value, proportion of targets with conserved target sites within the hosts’
pathway, proportion of targets with conserved target sites not within the
hosts’ pathway, q-value of the difference of these two proportions, and
Entrez gene IDs for all predicted targets are provided. The asterisk
behind a gene ID indicates a conserved target site for that target. It is
important to note, however, that a proportion calculated from these
gene IDs may differ from the proportion given, as the gene IDs are
based on agreement of two prediction methods, whereas the proportion
of conserved targets was calculated on predictions made by targetscan
only.
Additional file 6: Additional file 6 contains correlation data from
which Figure 2 and additional file 4 have been generated. For both
pathways, hosts and their predicted targets as well as correlation and p-
value are provided.
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